Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase NA 11Phase 1/2 8Phase 1 4Phase 2/3 2Phase 4 1Phase 3 1

Status

Recruiting 6Completed 6Active not recruiting 5Not yet recruiting 3Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 143Colorectal Neoplasms 97Carcinoma, Non-Small-Cell Lung 97Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 45Colonic Neoplasms 41Nasopharyngeal Carcinoma 39Leukemia, Myeloid, Acute 39Prostatic Neoplasms 38Lymphoma, Large B-Cell, Diffuse 38Uterine Cervical Neoplasms 36Neoplasm Metastasis 33Ovarian Neoplasms 32Esophageal Neoplasms 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 22Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Squamous Cell Carcinoma of Head and Neck 17Lymphoma, Mantle-Cell 17

Interventions

Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Biliary Tract Neoplasms × Clear all
NCT04401709 2022-06-15

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Samsung Medical Center

Phase 3 Unknown
490 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡